In a report released yesterday, Kostas Biliouris from BMO Capital maintained a Buy rating on Crispr Therapeutics AG (CRSP – Research Report), with a price target of $97.00.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Kostas Biliouris has given his Buy rating due to a combination of factors, highlighting Crispr Therapeutics AG’s promising pipeline and strategic positioning. The anticipated launch of Casgevy remains a crucial component of Crispr’s growth strategy, with expectations for significant revenue generation as approvals expand in the Middle East and the UK, alongside enhanced access facilitated by CMS CGT in the US.
Additionally, the upcoming clinical data from Crispr’s in vivo cardiovascular programs, CTX310 and CTX320, could potentially boost investor sentiment and offer substantial upside. With a solid cash position of approximately $2 billion, Crispr is well-equipped to navigate the challenging biotech environment and capitalize on strategic opportunities. Furthermore, the development of next-generation allogeneic products such as CTX112 and CTX131 enhances their competitive edge, particularly in autoimmune diseases, making it an attractive investment opportunity according to Biliouris.
In another report released today, JMP Securities also maintained a Buy rating on the stock with a $86.00 price target.